Advaxis Announces Promotion of Dr. Robert Petit and Daniel J. O’Connor
Advaxis,
Inc., (OTCBB: ADXS), a leader in developing the next
generation of immunotherapies for cancer and infectious diseases,
announced that the Board of Directors of Advaxis has elected Dr. Robert
Petit, currently Vice President of Clinical Operations and Medical
Affairs, to the position of Chief Scientific Officer. The Board has also
elected Daniel J. O'Connor, currently Senior Vice President, Chief Legal
and Business Development Officer, to Executive Vice President.
Promotions were made effective May 3, 2013.
“The excellent contributions Robert and Dan have made to Advaxis have
led to the Board’s decision to elevate their status within the company,”
commented Thomas A. Moore, Chairman and Chief Executive Officer of
Advaxis. “We look forward to working with our skilled and highly
experienced leadership team during the next stage of development at
Advaxis.”
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next
generation of immunotherapies for cancer and infectious diseases.
Advaxis immunotherapies are based on a novel platform technology using
live, attenuated bacteria that are bio-engineered to secrete an
antigen/adjuvant fusion protein(s) that is designed to redirect the
powerful immune response all human beings have to the bacterium to
the cancer itself.
ADXS-HPV is being evaluated in 5 clinical trials for HPV-associated
diseases: recurrent/refractory cervical cancer (India), locally advanced
cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier
NCT01266460), CIN 2/3 (US study, Clinical Trials.gov Identifier
NCT01116245), head & neck cancer (CRUK study, Clinical
Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study,
Clinical Trials.gov Identifier NCT01671488). Over fifteen (15) distinct
constructs are in various stages of development, developed directly by
the Company and through strategic collaborations with recognized centers
of excellence such as: the National
Cancer Institute, Cancer
Research – UK, the Wistar
Institute, the University
of Pennsylvania, the University
of British Columbia, the Karolinska
Institutet, and others. For more information please visit: advaxis.com
| Facebook
| twitter
| LinkedIn